EUVIMEDEUVIMED entdecken
Crossref

Human antibody combinations determined by epitope mapping of orthopoxvirus A33/A35 confer therapeutic protection in mice

Anqi Xia iD, Qiwei Jiang iD, Xiaojie Wang iD, Jie Liu, Jiannan Chen iD, Haozhe Zhao iD, Siyuan Sun, Wei Wu, Weiyu Jiang, Song Xue iD, Yi'ou Sha, Yingying Song und 16 weitere

Science Translational Medicine · 11.11.2026 · 18 (875)

DOI: 10.1126/scitranslmed.aeb2836 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 11.11.2026. Verfasst von Anqi Xia und 27 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, Qidong-Fudan Innovative Instit…. Hauptthemen laut MEDLINE: Epitope Mapping, Orthopoxvirus, Antibodies, Monoclonal, Antibodies, Viral. Die Arbeit nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences, Shanghai Municipal Science and Technology Major Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human infections with mpox virus (MPXV) since 2022 have resulted in more than 188,000 cases reported globally as of June 2026, highlighting the urgent need for effective therapeutics. Here, we recruited smallpox vaccinees and donors with incidental vaccinia virus (VACV) exposure and isolated a panel of human anti-A33/A35 monoclonal antibodies (mAbs) from the latter using recombinant MPXV A35 as a cross-reactive bait. These mAbs recognized four distinct nonoverlapping epitopes (epitopes 1 to 4) and one composite epitope (epitope 3 + 4) on MPXV A35 and exhibited cross-reactivity against multiple orthopoxviruses (OPXVs). Cryo–electron microscopy structural analysis revealed that the high-affinity epitope 3 + 4 mAb HD15 engages an epitope at the A35 dimer interface that is conserved across OPXVs. Combinations of mAbs targeting nonoverlapping epitopes mediated synergistic, Fc-dependent neutralization in vitro; conferred therapeutic protection against lethal VACV challenge; and reduced viral burden and disease severity after MPXV challenge in mice. Together, these findings establish a single-antigen, multiepitope strategy for the development of broadly protective therapeutics against OPXVs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epitope MappingOrthopoxvirusAntibodies, MonoclonalAntibodies, ViralAnimalsHumansEpitopesMiceCombined Antibody TherapeuticsFemaleVaccinia virusCryoelectron MicroscopyMice, Inbred BALB CCross Reactions

Substanzen

Antibodies, MonoclonalEpitopesAntibodies, ViralCombined Antibody Therapeutics

Autor:innen und Institutionen

  • Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, Qidong-Fudan Innovative Institution of Medical Sciences, Shanghai Frontiers Science Center of Pathog…
  • Key Laboratory of Jilin Province for Zoonoses Prevention and Control, State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Changchun, Jilin 130122, China.
  • Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 201210, China.
  • Department of Respiratory and Critical Care Medicine, Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, Jiangsu 214023, China.
  • Department of Clinical Laboratory, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117, China.
  • Department of Transfusion Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China.

ORCID-Profile: Anqi Xia, Qiwei Jiang, Xiaojie Wang, Jiannan Chen, Haozhe Zhao, Song Xue, Qianqian Zhang, Yaming Li, Liyuan Hu, Yidan Gao, Yuru Han, Jieliang Chen, Cong Zeng, Lu Lu, Rong Zhang, Rong Xia, Zhenghong Yuan, Xiao Li, Yixiao Zhang, Qiao Wang

Förderung

  • National Natural Science Foundation of China
  • Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences
  • Shanghai Municipal Science and Technology Major Project

Zitieren

APA

Xia, A., Jiang, Q., Wang, X., Liu, J., Chen, J., Zhao, H., Sun, S., Wu, W., Jiang, W., Xue, S., Sha, Y., Song, Y., Zhang, Q., Li, Y., Hu, L., Wang, H., Long, Y., Gao, Y., Han, Y., …, & Wang, Q. (2026). Human antibody combinations determined by epitope mapping of orthopoxvirus A33/A35 confer therapeutic protection in mice. Science Translational Medicine, 18(875). https://doi.org/10.1126/scitranslmed.aeb2836

Vancouver

Xia A, Jiang Q, Wang X, Liu J, Chen J, Zhao H, et al. Human antibody combinations determined by epitope mapping of orthopoxvirus A33/A35 confer therapeutic protection in mice. Science Translational Medicine. 2026;18(875). doi:10.1126/scitranslmed.aeb2836

BibTeX
@article{Xia2026,
  author = {Xia, Anqi and Jiang, Qiwei and Wang, Xiaojie and Liu, Jie and Chen, Jiannan and Zhao, Haozhe and Sun, Siyuan and Wu, Wei and Jiang, Weiyu and Xue, Song and Sha, Yi'ou and Song, Yingying and Zhang, Qianqian and Li, Yaming and Hu, Liyuan and Wang, Haiyu and Long, Yiming and Gao, Yidan and Han, Yuru and Chen, Jieliang and Zeng, Cong and Lu, Lu and Zhang, Rong and Xia, Rong and Yuan, Zhenghong and Li, Xiao and Zhang, Yixiao and Wang, Qiao},
  title = {Human antibody combinations determined by epitope mapping of orthopoxvirus A33/A35 confer therapeutic protection in mice},
  journal = {Science Translational Medicine},
  year = {2026},
  volume = {18},
  number = {875},
  doi = {10.1126/scitranslmed.aeb2836}
}
Kostenlos starten →